Adipotide
FTPP / Prohibitin-TP01
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
작용 메커니즘
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Research protocols in primates used 0.43mg/kg subcutaneously daily for 28 days. Resulted in 11% body weight loss. Human dosing not established. Very aggressive mechanism with significant renal toxicity risk.
연구 노트
Clinical Research Status
Adipotide demonstrated dramatic efficacy in a landmark 2012 primate study published in Science Translational Medicine, showing 11% body weight loss and 38% reduction in abdominal fat in obese rhesus monkeys over 28 days of treatment. Despite these impressive results, the severe kidney damage observed in treated animals has prevented progression to human clinical trials. No active clinical trial registrations for Adipotide in humans have been identified, and its development status remains uncertain with no recent publications from the original research group.
Key Published Findings
The targeting peptide CKGGRAKDC binds to prohibitin on the surface of blood vessels specifically in white adipose tissue, while the attached D(KLAKLAK)2 sequence disrupts mitochondrial membranes in endothelial cells, causing vascular collapse and subsequent adipocyte death. Treated monkeys showed dramatic reductions in body weight, BMI, abdominal circumference, and improvements in insulin resistance. Imaging studies confirmed selective destruction of adipose vasculature with corresponding fat tissue necrosis and reabsorption over the treatment period.
Safety Profile
The most significant safety concern is dose-dependent renal proximal tubule degeneration, likely due to prohibitin expression in kidney vasculature or renal filtration and accumulation of the peptide. Treated primates developed elevated BUN and creatinine levels, with histological evidence of tubular necrosis that was partially reversible upon treatment cessation. Additional concerns include the irreversible nature of vascular destruction in adipose tissue and the unknown long-term consequences of acute fat tissue necrosis on systemic inflammation and metabolic homeostasis.
Comparison to Related Compounds
Adipotide's mechanism is fundamentally different from all other fat loss compounds: rather than modulating metabolism, appetite, or lipolysis, it physically destroys the blood supply to fat tissue. GLP-1 agonists like semaglutide achieve comparable weight loss through appetite suppression without organ toxicity, making them far safer alternatives despite slower onset. The targeted vascular disruption approach was originally developed for cancer therapy (tumor angiogenesis inhibition) and represents a repurposing that may carry inherent toxicity risks in non-tumor tissue.
Community Observations
Despite significant interest generated by the primate study results, human self-experimentation with Adipotide is extremely rare due to legitimate fears of irreversible kidney damage. Online communities generally regard Adipotide as a cautionary example of dramatic efficacy coupled with unacceptable toxicity, often referenced in discussions about risk-reward calculations in experimental compound use. The compound is occasionally available from gray market peptide sources, but knowledgeable community members consistently advise against its use given the availability of safer alternatives for fat loss.
반감기
~30-60 minutes
재조성
Bacteriostatic water (BAC)
보관
건조한 상태
Refrigerate 2-8C. Protect from light.
재조성된 상태
Refrigerate 2-8C. Use within 7 days.
미국 법적 상태
또는 알려진 이름으로
자주 묻는 질문
Adipotide란 무엇인가요?
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
Adipotide는 어떻게 작용하나요?
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
Adipotide의 미국 규제 현황은 어떤가요?
Research chemical (not FDA-approved)
Adipotide의 반감기는 얼마인가요?
~30-60 minutes
Adipotide의 다른 이름은 무엇인가요?
FTPP, Prohibitin-TP01
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기